Results 161 to 170 of about 824,117 (206)

CCR5 blockade inhibits menstrual-driven proinflammatory T cell infiltration into the cervicovaginal mucosa of women. [PDF]

Sci Adv
Swaims-Kohlmeier A, Vidal P, Varughese R, Hardnett FP, Daniel GA, Garcia-Lerma JG, Ofotokun I, Sheth AN.   +7 more
europepmc   +1 more source

Unveiling CCL5: the master regulator of breast cancer progression and immune evasion. [PDF]

Breast Cancer Res
Mu J, Zhang M, Chen Q, Liu W, Feng W, Zhang Y.   +5 more
europepmc   +1 more source

The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents.

Bioorganic & Medicinal Chemistry Letters, 2012
Yan Zhang, Christopher K. Arnatt, Feng Zhang, Jian-Nan Wang, Kendra M. Haney, Xian-Jun Fang   +5 more
semanticscholar   +1 more source

CCR5 as a Therapeutic Target in HIV Disease: From CRISPR/Cas9 Gene Editing to Maraviroc-Mediated Inhibition. [PDF]

Viruses
Iqbal U, Khalid K, Shaltout M, Yukselten Y, Sutton RE.   +4 more
europepmc   +1 more source

T cell-derived CCL5 drives macrophage immunometabolic remodeling in chronic prostatitis via the CCR5-ERK-PKM2/HIF-1α axis. [PDF]

Redox Biol
Liu X, Li B, Dou X, Ju W, Liu W, Zhang F, Jin C, Lu Y, Wang R, Chen X, Liang C, Zhang M.   +11 more
europepmc   +1 more source

CCR5Δ32 Polymorphism and Inflammatory Bowel Disease: A Case-Control and Genotype-Phenotype Study in a Polish Population. [PDF]

Int J Mol Sci
Petryszyn P, Koj K, Dudkowiak R, Gruca A, Poniewierka E, Głowacka K.   +5 more
europepmc   +1 more source

Maraviroc Inhibits SARS-CoV-2 Through Variant-Dependent Effects on Viral Entry and Mpro Activity Using Single-Round Infectious Particle and Virus-like Particle Models. [PDF]

Viruses
Le UNP, Chen PJ, Chu LW, Arifin JC, Chen CH, Chen YH, Su WC, Hsueh PR, Ping YH, Lin CW.   +9 more
europepmc   +1 more source

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. [PDF]

Antimicrob Agents Chemother, 2016
Kuwata T, Enomoto I, Baba M, Matsushita S.   +3 more
europepmc   +1 more source

CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma. [PDF]

J Transl Med
Tan M, Chen Y, Yang J, Wang Q, Li L.
europepmc   +1 more source

I-TAC (CXCL11) is a natural antagonist for CCR5

, 2004
Paoletti, Samantha, Petkovic, Vibor, Uguccioni, Mariagrazia, Gerber, Basil, Moghini, Christian   +4 more
core   +1 more source